NDMA, or N-nitrosodimethylamine, is not a drug itself. It’s a chemical contaminant that has been found in several common medications, triggering major recalls and safety warnings. NDMA is a type of nitrosamine, a family of compounds classified as a probable human carcinogen by the EPA, the International Agency for Research on Cancer, and the U.S. National Toxicology Program. It appears as a yellow, odorless liquid at room temperature and is produced industrially only in tiny quantities for research purposes.
The reason you’ve likely heard of NDMA is that it showed up where it shouldn’t: inside pills taken daily by millions of people, including blood pressure medications and the popular heartburn drug Zantac. The FDA now sets a strict acceptable daily intake limit of 96 nanograms per day for NDMA in pharmaceutical products.
Why NDMA Is Considered Dangerous
NDMA causes cancer in animal studies, and every major health agency treats it as a likely cancer risk in humans. The EPA classifies it as a “probable human carcinogen” (category B2). The International Agency for Research on Cancer places it in Group 2A, meaning “probably carcinogenic to humans.” The U.S. National Toxicology Program calls it “reasonably anticipated to be a human carcinogen.”
To put the risk in perspective, NDMA isn’t something that causes harm from a single exposure. The concern is long-term, repeated intake at levels above what the body can safely process. The 96-nanogram daily limit the FDA established is designed to keep lifetime cancer risk extremely low, roughly one additional case per 100,000 people exposed over 70 years.
How NDMA Gets Into Medications
NDMA doesn’t belong in any drug. It forms as an unintended byproduct during manufacturing when certain chemical ingredients react with each other under the wrong conditions. The basic recipe for NDMA contamination involves two things combining: an amine (a nitrogen-containing compound common in drug ingredients) and a nitrite (a reactive nitrogen compound). When these meet in acidic conditions, they can produce nitrosamines like NDMA.
The sources of contamination are surprisingly varied. Solvents reused between manufacturing batches can carry residual amines. Tap water used in production may contain low levels of nitrites from environmental sources. Raw materials purchased from suppliers sometimes arrive already containing trace nitrosamines or the chemical precursors that form them. Even the air itself plays a role: manufacturing processes that use forced air at high temperatures, like fluid bed drying, can introduce nitrogen oxides from the atmosphere that react with drug ingredients.
In some cases, the contamination traces back to something as mundane as shared storage vessels. The FDA has found nitrosamines in fresh solvents that picked up impurities during transfer between tanks. Recovered and recycled solvents pose a particular risk because they may contain leftover reactive chemicals from previous production runs.
Which Medications Have Been Affected
The NDMA contamination problem first made headlines in 2018 when it was discovered in valsartan, a widely prescribed blood pressure medication. Testing revealed that a change in the manufacturing process at a major supplier had introduced NDMA into the drug, and batches had been contaminated for years before anyone noticed. Recalls quickly expanded to other blood pressure drugs in the same chemical family, called sartans.
The biggest recall came in April 2020, when the FDA requested the removal of all ranitidine products (brand name Zantac) from the market. Ranitidine was different from the valsartan situation. Rather than contamination during manufacturing, the ranitidine molecule itself was unstable. Research showed that the drug broke down and generated NDMA over time, especially when stored at higher temperatures. A study found that storing ranitidine tablets at 60°C (140°F) for just one week significantly increased NDMA levels, with moisture and oxygen accelerating the process. This meant NDMA levels could climb during shipping, warehouse storage, or even sitting in a medicine cabinet, making it impossible to guarantee the drug was safe by the time someone took it.
Metformin, one of the most commonly prescribed diabetes medications worldwide, also underwent scrutiny and selective recalls after some batches tested above the acceptable NDMA limit.
How NDMA Contamination Is Detected
Detecting NDMA at the nanogram level requires extremely sensitive lab equipment. The FDA developed and validated testing methods using a technique called liquid chromatography paired with high-resolution mass spectrometry. In simple terms, the process separates a drug sample into its individual chemical components, then measures the precise mass of each molecule to identify even trace amounts of NDMA.
This technology is sensitive enough to detect contamination at parts-per-billion levels. The FDA uses these methods to test drug products during investigations and to verify that manufacturers are meeting safety limits. Before the valsartan crisis, this kind of routine nitrosamine screening wasn’t standard practice in pharmaceutical manufacturing, which is partly why the contamination went undetected for so long.
What Changed After the Recalls
The NDMA discoveries triggered a fundamental shift in how drug manufacturers handle nitrosamine risks. The FDA now requires pharmaceutical companies to evaluate their entire manufacturing process for conditions that could produce nitrosamines. This includes auditing raw material suppliers, testing water sources, examining solvent recovery procedures, and reviewing every step where amines and nitrites could come into contact.
For patients, the practical impact has been straightforward. If you were taking ranitidine, it’s no longer available in any form. Several alternative heartburn medications that don’t carry the same NDMA risk remain on the market. If you were taking a blood pressure medication or metformin batch that was recalled, the guidance was to switch to an unaffected batch or an alternative medication rather than stop treatment abruptly. The cancer risk from short-term NDMA exposure at low levels is far smaller than the immediate health risk of untreated high blood pressure or uncontrolled blood sugar.
NDMA Beyond Medications
NDMA isn’t unique to pharmaceuticals. It also shows up in drinking water, food (particularly cured and smoked meats), tobacco smoke, and certain industrial settings. The EPA sets a drinking water threshold of 0.00007 milligrams per liter for a cancer risk level of one in 10,000. Your daily exposure from all these sources combined is typically very small, but the pharmaceutical contamination cases were notable because they represented a concentrated, repeated dose delivered directly in pill form over months or years.
The contamination crisis also revealed how a single change in a manufacturing process, sometimes at a facility on the other side of the world, could quietly introduce a carcinogen into medications trusted by millions. The regulatory overhaul that followed has made nitrosamine testing a permanent part of drug quality control, a safeguard that simply didn’t exist before 2018.